The study included 268 cataract surgery patients. BromSite was administered the day of surgery and twice a day for two weeks post-surgery. The trial, designed to determine the safety and efficacy of the treatment, showed promising results.
More Articles on Ophthalmology:
American Academy of Ophthalmology Cautionary Campaign Gains Public Awareness
Las Vegas New Eyes, Eye Care Associates Partner
OptiMedica Laser System Clinical Presentations to be Shown at ASCRS 2013
